# US 2026/0083673 A1 · Oil-in-water emulsions for topical administration and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083673 A1
- Document ID: US20260083673A1
- Status: Published application
- Kind: A1
- Application number: 19/113,506
- Filed: 2023-09-22
- Published: 2026-03-26
- Earliest claimed: 2022-09-23
- Assignees: Institut National de la Sante et de la Recherche Medicale; Centre National De La Recherche Scientifique; Université Paris Cité; Universite Paris-Saclay
- Applicants: Institut National De La Santé Et De La Recherche MéDicale; Centre National De La Recherche Scientifique; Universite Paris Cite; Universite Paris-Saclay
- Inventors: Laurence MICHEL; Maxime SINTÈS; Claire ALBERT; Florence AGNELY; Mohamed Amine BELADJINE; Nicolas HUANG; Nicolas TSAPIS; Liasmine HAINE HABLAL
- Web page: https://patentgrep.com/patent/US20260083673A1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 31/728: Hyaluronic acid
- A61K 38/13: Cyclosporins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic/injured area).

## Claims

### Claim 1

Oil-in-water Pickering emulsion comprising:
an oil phase comprising a first therapeutic agent,
an aqueous phase,
polyester nanoparticles comprising a second therapeutic agent,
wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase,
and wherein the aqueous phase comprises hyaluronan.

### Claim 2 (depends on 1)

The oil-in-water Pickering emulsion according to claim 1, wherein the pH of the emulsion is from 4.5 to 6.5.

### Claim 3 (depends on 1)

The oil-in-water Pickering emulsion according to claim 1, wherein the oil phase comprises at least one oil chosen from fatty acids, fatty acid esters, vegetable oils, mineral oils, and mixtures thereof.

### Claim 4 (depends on 3)

The oil-in-water Pickering emulsion according to claim 3, wherein the fatty acid esters are selected from triglycerides of medium-chain fatty acids.

### Claim 5 (depends on 1)

The oil-in-water Pickering emulsion according to claim 1, wherein the droplets forming the oil phase have a size distribution ranging from 1 μm to 100 μm, as measured by dynamic light scattering.

### Claim 6 (depends on 1)

The oil-in-water Pickering emulsion according to claim 1, wherein the polyester is selected from polylactic acid, polyglycolic acid, copolymers of lactic acid and glycolic acid, copolymers of lactic acid, glycolic acid and ethylene glycol, polyorthoesters, polyanhydrides, polylactones, polymalic acid, and mixtures thereof.

### Claim 7 (depends on 6)

The oil-in-water Pickering emulsion according to claim 6, wherein the polyester is poly(lactic-co-glycolic acid).

### Claim 8 (depends on 1)

The oil-in-water Pickering emulsion according to claim 1, wherein the first therapeutic agent is selected from anti-inflammatory agents and natural or semisynthetic analogs derived from metabolites of vitamin E.

### Claim 9 (depends on 1)

The oil-in-water Pickering emulsion according to claim 1, wherein the second therapeutic agent is an immunosuppressive agent.

### Claim 10 (depends on 1)

The oil-in-water Pickering emulsion according to claim 1, wherein the oil phase further comprises an antioxidant.

### Claim 11 (depends on 1)

The oil-in-water Pickering emulsion according to claim 1, wherein the molar mass of hyaluronan is from 5000 g/mol to 5000000 g/mol.

### Claim 12 (depends on 1)

The oil-in-water Pickering emulsion according to claim 1, wherein the concentration of hyaluronan in the aqueous phase calculated as the mass of hyaluronan in grams contained in 100 mL of the aqueous phase is from 0.15% to 5%.

### Claim 13 (depends on 1)

The oil-in-water Pickering emulsion according to claim 1, wherein
the first therapeutic agent is Tacrolimus, and
the second therapeutic agent is calcitriol.

### Claim 14 (depends on 1)

Pharmaceutical composition comprising the oil-in-water Pickering emulsion according to claim 1 and at least one pharmaceutically acceptable excipient.

### Claim 15 (depends on 1)

A method of treating a dermatologic pathology in a human or animal in need thereof, comprising administering to the human or animal a therapeutically effective amount of the oil-in-water Pickering emulsion of claim 1.
